Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
China · Delayed Price · Currency is CNY 15.24
-0.44 (-2.81%)
At close: Nov 13, 2026
SHE:301246 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 6,047 | 9,920 | 5,385 | 10,392 | - | - | |
Market Cap Growth | -30.66% | 84.22% | -48.18% | - | - | - |
Enterprise Value | 5,032 | 9,203 | 4,068 | 8,758 | - | - |
Last Close Price | 15.24 | 24.96 | 13.48 | 25.78 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 20.02 | 83.33 | 104.64 | 119.22 | - | - |
PS Ratio | 2.36 | 5.12 | 3.04 | 5.06 | - | - |
PB Ratio | 1.30 | 2.23 | 1.24 | 2.38 | - | - |
P/TBV Ratio | 1.35 | 2.32 | 1.29 | 2.49 | - | - |
P/OCF Ratio | 54.32 | - | - | 294.81 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.96 | 4.75 | 2.30 | 4.26 | - | - |
EV/EBITDA Ratio | 9.57 | 28.93 | 19.10 | 39.79 | - | - |
EV/EBIT Ratio | 16.46 | 78.89 | 115.30 | 136.98 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.14 | 0.12 | 0.09 | 0.08 | 0.21 | 0.05 |
Debt / EBITDA Ratio | 1.27 | 1.67 | 1.75 | 1.58 | 1.24 | 0.18 |
Net Debt / Equity Ratio | -0.22 | -0.30 | -0.38 | -0.42 | -0.02 | -0.02 |
Net Debt / EBITDA Ratio | -1.93 | -4.17 | -7.75 | -8.32 | -0.15 | -0.09 |
Net Debt / FCF Ratio | 6.89 | 3.89 | 9.38 | 4.17 | 0.18 | 0.66 |
Asset Turnover | 0.42 | 0.32 | 0.31 | 0.43 | 0.65 | 0.75 |
Inventory Turnover | 6.71 | 5.48 | 6.88 | 6.67 | 4.40 | 2.89 |
Quick Ratio | 2.04 | 2.26 | 2.35 | 3.20 | 0.93 | 1.01 |
Current Ratio | 2.57 | 2.66 | 2.68 | 3.50 | 1.26 | 1.67 |
Return on Equity (ROE) | 6.75% | 2.67% | 1.18% | 2.69% | 22.93% | 34.51% |
Return on Assets (ROA) | 3.10% | 1.22% | 0.38% | 0.84% | 5.18% | 10.62% |
Return on Invested Capital (ROIC) | 7.03% | 3.22% | 1.16% | 2.46% | 12.86% | 23.80% |
Return on Capital Employed (ROCE) | 5.90% | 2.40% | 0.80% | 1.40% | 10.20% | 19.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.99% | 1.20% | 0.96% | 0.84% | - | - |
FCF Yield | -2.43% | -3.44% | -3.27% | -4.23% | - | - |
Dividend Yield | 0.33% | 0.20% | 0.22% | 0.19% | - | - |
Payout Ratio | 11.98% | 23.58% | 59.97% | 61.72% | 3.44% | 0.45% |
Buyback Yield / Dilution | -1.46% | 0.42% | -2.71% | -10.02% | 0.00% | -0.13% |
Total Shareholder Return | -1.13% | 0.62% | -2.49% | -9.83% | 0.00% | -0.13% |